Blockade of IL-3 is a promising novel strategy for RA therapy
Rheumatoid arthritis (RA) is a chronic, systemic inflammatory
disorder that attacks the joints producing an inflammatory synovitis. About 1% of the world‘s population is afflicted by rheumatoid arthritis, which is associated with high costs and, if not treated appropriately, with a reduction in life expectancy. Current treatment options include small molecules like methotrexate or biologics like TNFa-blockers, but about 20 % of patients show little or no response to currently available therapies or suffer from severe long term side effects like infections (i.e. tuberculosis, viral brain infections) or cancer (i.e. lymphomas). Clearly, an effective RA drug has blockbuster potential as shown by TNFa-blocker Humira® (Abbott Laboratories) with annual worldwide sales of 4.5 Billion USD in 2008 (data by Medtrack).
Further Information: PDF
Bayerische Patentallianz GmbH
Phone: +49 89 5480177-0
Contact
Peer Biskup
Media Contact
All latest news from the category: Technology Offerings
Newest articles
The Sound of the Perfect Coating
Fraunhofer IWS Transfers Laser-based Sound Analysis of Surfaces into Industrial Practice with “LAwave”. Sound waves can reveal surface properties. Parameters such as surface or coating quality of components can be…
Customized silicon chips
…from Saxony for material characterization of printed electronics. How efficient are new materials? Does changing the properties lead to better conductivity? The Fraunhofer Institute for Photonic Microsystems IPMS develops and…
Acetylation: a Time-Keeper of glucocorticoid Sensitivity
Understanding the regulatory mechanism paves the way to enhance the effectiveness of anti-inflammatory therapies and to develop strategies to counteract the negative effects of stress- and age-related cortisol excess. The…